Kornimate/medical-research-clean huggingface dataset:
effect of vitamin d injection on hypertrophic scars and keloids

Conditions: Dermatologic Disease

Summary: scars and keloids cause patients severe morbidity and psychological distress. hypertrophic scars rise above the skin but stay within the scar boundaries, while keloids expand. the development of keloids and hypertrophic scars is a consequence of insufficient wound healing. these lesions are distinguished by excessive ecm deposition. excessive ecm deposition is caused by increased inflammatory and proliferative processes and decreased remodeling activities. these scarring lesions are also linked to genetic and systemic causes


Eligibility criteria:
inclusion criteria: - age from 12 years to 50 years. patients with hypertrophic scars and keloids exclusion criteria: age below 12 years and above 50 years. patients received other treatment modalities for hypertrophic scars and keloids. systemic and other skin diseases. patients were already receiving supplemental vitamin d.
contrast-enhanced whole-heart coronary magnetic resonance angiography at 3.0-t: a multicenter trial

Conditions: Coronary Artery Disease

Summary: the multicenter study evaluates the diagnostic performance of 3.0 t contrast-enhanced whole-heart coronary mra in patients with suspected coronary artery disease.

this is a multicenter trial evaluated the diagnostic ability of 3.0 t contrast-enhanced whole-heart coronary mra to detect significant coronary artery stenosis among patients with suspected cad. a total of 272 patients will be prospectively enrolled from 8 cities in china.

Eligibility criteria:
inclusion criteria: * suspected cad, scheduled for dsa * sinus rhythm exclusion criteria: * contraindications to mr examination: pacemaker, intraauricular implants, intracranial clips, thoracotomy, claustrophobia, orthopnea * acute coronary syndrome * atria fibrillation * coronary stents * bypass grafts * renal insufficiency (estimated glomerular filtration rate assessed by creatinine clearance \<60 ml/min/1.73 m2)

Keywords: coronary artery magnetic resonance angiography coronary artery disease multicenter trial cardiac mri
evaluation of outcomes following in-office tympanostomy using the tula® system: a prospective, multi-center registry

Conditions: Otitis Media With Effusion; Acute Otitis Media; Otitis Media

Summary: this prospective, single-arm, multicenter registry is being conducted to collect real world post-market data from patients aged from 6 months to 17 years of age who are undergoing an in-office ear tube placement procedure (tympanostomy) using the tula® system. the registry will include up to 20 centers in the us and up to 200 patients for the initial evaluation. the fda-approved tula system includes the tula iontophoresis system (ips) with tymbion™ otic anesthetic for local anesthesia of the ear drum and the tula tube delivery system (tds) for ear tube placement. clinical research established the safety, efficacy and tolerability of this system for in-office procedures in the pediatric population. patients will be treated and evaluated according to standard medical care. outcome data is collected up to 6 months following extrusion or removal of their tube(s).


Eligibility criteria:
inclusion criteria: * patients ages 6 months through 17 years of age (inclusive) at time of tympanostomy in-office using the tula® system * patients who are candidates for in-office tube placement using the tula system according to the system instructions for use exclusion criteria: * patients who are wards are not included

Keywords: otitis media pediatric tympanostomy office procedure local anesthesia
a clinical cohort study of safety and effectiveness of venous thromboembolism prophylaxis in critical ill patients

Conditions: Venous Thromboembolism; Hemorrhage

Summary: the purpose of this study is to analyze the effect of the prophylaxis of venous thromboembolism in the critical ill patients, and at the same time, to find out the risk of venous thromboembolism and hemorrhage events occurred under the prophylaxis.


Eligibility criteria:
inclusion criteria: * all the patients in icus estimated time in icu mare than 48h exclusion criteria: * estimated time in icu less than 48h refused to attend
intensive insulin therapy in non-diabetic patients with acute myocardial infarction and hyperglycaemia

Conditions: Diabetes; Hyperglycemia; Acute Myocardial Infarction

Summary: hyperglycemia at admission has been associated with bad prognosis in patients with acute myocardial infarction (ami). the clinical benefit of intensive treatment with insulin has been evaluated in diabetic patients admitted to intensive care units. the aim of our study was to assess the short-term effects and the safety of strict glycemic control in subjects with ami and hyperglycemia without a previous history of diabetes.

twenty-eight non-previously diabetic patients admitted with ami and hyperglycemia were randomized to two treatment arms, administered during the first 48 hours: the intensive group (n=13) received intravenous insulin with target glycemia levels of 80-110mg/dl, while the conventional group (n=15) received subcutaneous insulin only when glycemia was ³ 160mg/dl. high-sensitivity c-reactive protein (hs-crp) was determined at 48 hours and before discharge and an oral glucose tolerance test (ogtt) was performed at 1 month.

Eligibility criteria:
inclusion criteria: 1. confirmed diagnosis of ami, either with or without st segment elevation 2. presence of high blood glucose at admission with no previously known diabetes mellitus (dm) exclusion criteria: 1. age under 18 years old 2. history of dm 3. presence of other cardiopathies (dilated cardiomyopathy, valvular or hypertrophic heart disease) 4. unstable ami patients (haemodynamic instability or arrhythmic disorders) 5. platelet aggregation or coagulation disorders 6. severe conditions with an estimated short (under 1 year) life expectancy 7. participation in other trials 8. patient refusal to participate in the study
behçet's disease and eosinophil cationic protein

Conditions: Behçet's Disease

Summary: eosinophil cationic protein (ecp) is a matrix protein of eosinophils and has been reported to reflect eosinophil activity. few studies have examined the role of eosinophils in the pathogenesis of behçet's disease. the purpose of the present study is to investigate the serum ecp levels in bd and its relation to clinical activity.

behçet's disease (bd) is a systemic vasculitis, characterized by recurrent oral aphthae, genital ulcers, uveitis, skin lesions, arthritis, gastrointestinal and neurologic manifestations. there has been a growing interest in research on the pathogenesis of the disease. eosinophils has been implicated in the vascular injury associated with several vasculitis syndromes like churg strauss syndrome, temporal arteritis and henoch-schonlein purpura. in behçet patients, serum ige and eosinophils have been reported to be comparable with the controls but eosinophil activity has not been studied extensively. eosinophil cationic protein (ecp) is a matrix protein of specific granules of eosinophils with considerable capacity to damage tissue and cells and has been reported to reflect eosinophil activity. increased serum levels of ecp has been reported in patients with seasonal allergic rhinitis. several immunomodulatory features of ecp has been reported, such as inhibition of the proliferative t-lymphocyte response to antigen, immunoglobulin production, proliferation of plasma cell lines and upregulation of icam-1. procoagulant effects of ecp has also been reported. the present study was conducted in patients without usage of any confounding drugs that can effect serum ecp levels. the purpose of this study was to investigate the serum ecp levels in bd and its relation to the clinical activity. forty-seven consecutive patients with bd (22 active, 25 inactive) meeting international study group criteria , 21 age and sex matched patients with allergic rhinitis and 21 apparently healthy controls were evaluated prospectively in rheumatology-immunology outpatient clinic. clinical activity was defined according to the criteria proposed by "behcet's disease research committee of japan" . activity scoring was made according to the "behçet's disease research committee of japan" which was proposed in 1994. organ involvements of the patients were summarized. patients on corticosteroids or immunosuppressives were excluded. colchicine was stopped 10 days prior to the blood collection in inactive patients. blood was drawn from the active patients before starting treatment. cases with any allergy history or parasitosis were excluded.

Eligibility criteria:
inclusion criteria: * consecutive behçet patients who gave the written informed consent were included. exclusion criteria: * patients on corticosteroids or immunosuppressives were excluded.cases with any allergy history or parasitosis were excluded.

Keywords: behçet's disease eosinophil cationic protein eosinophils
low-molecular-weight heparin (lmwh) versus unfractionated heparin (ufh) in pregnant women with recurrent abortion secondary to antiphospholipid syndrome

Conditions: Recurrent Abortion

Summary: the aim of this study is to compare the efficacy and safety of low molecular weight heparin (lmwh) plus low dose aspirin (lda) with unfractionated heparin(ufh) plus lda in women with recurrent pregnancy loss associated with antiphospholipid syndrome (aps).

women with antiphospholipid syndrome (aps) have live birth rates as low as 10% in pregnancies without pharmacological treatment. low dose aspirin (lda) ,unfractionated heparin(ufh) , low molecular weight heparin (lmwh) , prednisone, and intravenous immunoglobulin (ivig) have been used either alone or in combination in order to improve the live birth rate in aps positive women with recurrent miscarriage. a cochrane review of 13 randomized or quasi-randomized, controlled trials of various management options of pregnant women with a history of pregnancy loss and apl, revealed that combined ufh and aspirin was the treatment of choice which reduced pregnancy loss by 54% . during the past decade , low molecular weight heparins were widely used in the prophylaxis and treatment of patients with venous or arterial thrombosis ,with an efficacy and safety superior or at least equivalent to that of ufh .although recent studies reported the use of lmwh in the management of patients recurrent pregnancy loss secondary to antiphospholipid syndrome resulted in encouraging results . it is not clear whether the efficacy and safety of lmwh is equivalent to that of ufh . although lmwh is more expensive than ufh . lmwh has longer half life , greater bioavailability , more stable dose-response relationship than ufh and therefore can be administered once daily. furthermore, lmwh requires less frequent monitoring than ufh and and has less adverse effect on bone mineral density and platelet count .these advantages make lmwh more attractive for the patients and physicians than ufh . there are only two studies which compared the efficacy of lmwh plus lda with that of ufh plus lda in the management of pregnant women with recurrent pregnancy loss secondary to aps. in addition ,no randomized controlled study has yet compared the efficacy of lmwh plus lda with ufh plus lda. the aim of this study is to compare the efficacy and safety of low molecular weight heparin (lmwh) plus low dose aspirin (lda) with unfractionated heparin(ufh) plus lda in women with recurrent pregnancy loss associated with antiphospholipid syndrome (aps).

Eligibility criteria:
inclusion criteria: * patients with a minimum of three consecutive pregnancy losses before 10 weeks gestation * positive lupus anticoagulant and/or anticardiolipin antibodies (igg and igm) on at least two occasions twelve weeks apart . * age between 19 - 37 years, * body mass index between 19-30 exclusion criteria: * parental chromosomal abnormalities * uterine abnormalities * luteal phase defect * systemic lupus erythematosus * previous thromboembolism * sensitivity to aspirin.

Keywords: recurrent abortion antiphospholipid syndrome unfractionated heparin low molecular weight heparin
a clinical study to evaluate the efficacy and safety of min-102 (imp) in male amn patients.

Conditions: Adrenoleukodystrophy

Summary: this is a phase ii/iii, randomized, double-blind, placebo-controlled, multicenter, two parallel-group study in male patients with the amn phenotype of x-linked adrenoleukodystrophy (x-ald) to assess the efficacy and safety of min-102 treatment. study sites will consist of specialist referral centers experienced in the management of adrenoleukodystrophy (ald).


Eligibility criteria:
inclusion criteria: * male and between 18-65 years of age. * diagnosed with x-linked adrenoleukodystrophy (x-ald) based on elevated vlcfa and genetic testing. * clinical evidence of spinal cord involvement. exclusion criteria: * any other chronic neurological disease with signs of spastic paraplegia, such as hereditary spastic paraplegia, multiple sclerosis, etc. * presence of inflammatory (gd-enhancing) mri lesions or any abnormality other than those mentioned in the inclusion criteria. * known type 1 or type 2 diabetes. * known intolerance to pioglitazone or any other thiazolidinedione. * taking or have taken honokiol, pioglitazone or other thiazolidinediones within the 6 months prior to screening. * previous bone marrow transplantation. * previous or current history of cancer (other than treated basal cell carcinoma). * previous or current history of congestive heart failure.
heart rate variability in depression

Conditions: Major Depressive Disorder

Summary: the purpose of this study is to understand if there is a relationship between the way that emotions are regulated by the brain and the way that heart rate is regulated by the brain. the study also seeks to understand whether having depression changes the way that emotions and heart rate are regulated.


Eligibility criteria:
inclusion criteria: * ages 18-65 years * able to understand and provide informed consent * male and female depressed subjects: * current diagnosis of major depressive disorder (mdd) and currently in an major depressive episode (mde) * quick inventory of depressive symptomology (qids-sr16) score of 11 or greater * anticipated treatment with ketamine infusion for depression exclusion criteria: * current daily use of tricyclic antidepressants * current diagnosis of cardiac arrhythmia or heart failure * pregnancy * current use of cardiac medications of the class beta-blockers * current treatment with deep brain stimulation for any reason healthy controls: * current psychiatric treatment, including use of antidepressants or daily use of anxiolytic medication depressed subjects: * previous history of ketamine infusion for depression * psychotic symptoms * active co-morbid psychiatric diagnosis including anxiety disorder or personality disorder that significantly affects the current clinical condition, as determined by medical records

Keywords: heart rate
histopathological examination of iris tissue in buphthalmos

Conditions: Iris Disease

Summary: to revise the etiology of the primary congenital glaucoma in some infants.

combined trabeculotomy trabeculectomy with mitomycin c was done in 11 eyes. histopathological examination of the peripheral iris tissue specimen was done in all cases.

Eligibility criteria:
inclusion criteria: * infants under age of 2 years * 1ery glaucoma exclusion criteria: * infants more than 2 years * 2ery glaucoma * previous glaucoma surgery
imageready(tm) mr conditional pacing system clinical study

Conditions: Bradycardia; Sinus Node Dysfunction

Summary: the objective of the samurai clinical study is to collect data to confirm the safety, performance and effectiveness of the imageready system for use in the magnetic resonance imaging (mri) environment when used in accordance with the conditions of use included in the boston scientific mri technical guide


Eligibility criteria:
inclusion criteria: * subject must have the imageready system as their initial (de novo) pacing system implant * subject has a class i or ii indication for implantation of a single or dual chamber pacemaker according to the acc/aha/hrs, or esc guidelines, as appropriate per geography * subject is able and willing to undergo an mri scan without intravenous sedation * subject is willing and capable of providing informed consent (which can include the use of a legally authorized representative (lar) for documentation of informed consent) and participating in all testing/ visits associated with this clinical study at an approved clinical study center and at the intervals defined by this protocol * subject is age 18 or above, or of legal age to give informed consent specific to state and national law exclusion criteria: * subject has or has had any pacing or icd system implants * subject has any mr unsafe implants or devices with an unknown mr status, including mr unsafe sternal wires, neurostimulators, biostimulator, metals or alloys, per labeling of each implant * subject has any mr conditional implants or devices that impact the ability to conduct this protocol * subject needs or will need another mr scan within 14 weeks of system implant, other than that required by the samurai study * subject has a known or suspected sensitivity to dexamethasone acetate (dxa) * subject has a mechanical tricuspid heart valve * subject is enrolled in any other concurrent study, with the exception of local mandatory governmental registries and observational studies/registries\* that are not in conflict and do not affect the following: * schedule of procedures for the samurai study (i.e. should not cause additional or missed visits); * samurai study outcome (i.e. involve medications that could affect pacing thresholds); * conduct of the samurai study per gcp/ iso 14155:2011/ local regulations * subjects with documented permanent or persistent af where the physician intends to implant a dual chamber pulse generator (single chamber vvir pulse generators are acceptable) * subject is currently on the active heart transplant list * subject has documented life expectancy of less than 12 months * women of childbearing potential who are or might be pregnant at the time of study enrollment or imageready mr conditional pacing system implant (method of assessment upon physician's discretion) * subjects currently requiring dialysis

Keywords: single chamber pacing dual chamber pacing mri mr scans
iliopsoas nerve block and femoral nerve block in hip fracture surgeries

Conditions: Iliopsoas Nerve Block; Femoral Nerve Block; Hip Fracture Surgeries

Summary: this study aims to compare iliopsoas nerve block (ipb) to femoral nerve block (fnb) regarding pain control, patient satisfaction, and early ambulation in patients undergoing hip fracture surgeries

hip fractures are among the most frequent fractures seen in the emergency department and orthopedic trauma teams. the terms hip fracture and neck of femur fracture are used synonymously. both terms describe a proximal femur fracture between the femoral head and 5 cm distal to the lesser trochanter. iliopsoas nerve block (ipb) is a promising motor-sparing analgesic technique that selectively targets the sensory branches of the hip joint originating from the femoral nerve and accessory obturator nerve, sparing the motor supply of quadriceps muscles. a femoral nerve block (fnb) is a simple nerve block that can be performed easily without or under ultrasound guidance. under ultrasound guidance, the femoral artery and femoral nerve were identified clearly, and a needle was inserted using an in-plane approach from the lateral to the medial direction. once the needle tip's position was confirmed, 10 ml of 0.5% bupivacaine was injected adjacent to the femoral nerve.

Eligibility criteria:
inclusion criteria: * age from 18 to 65 years. * both sexes. * american society of anesthesiologists (asa) physical status i and ii. * patients who are scheduled for elective surgical correction of hip fracture either through open fracture internal fixation (orif), partial hip arthroplasty or total hip arthroplasty. exclusion criteria: * refusal to participate. * coagulopathy. * patients with a history of drug allergies to study drugs. * inability to cooperate.
phase i/ii study of neuroendocrine dysfunction in patients with closed head injuries

Conditions: Brain Injury

Summary: objectives: i. determine the incidence of neuroendocrine dysfunction in patients with closed head injuries admitted to the transitional learning community in galveston, texas, for rehabilitation.

protocol outline: phase i: patients undergo fasting for urine and blood endocrine assessments. first morning urine is collected for measurement of 6-sulphatoxymelatonin (6-smt). following a medical history and a physical examination, patients undergo measurement of serum levels of free thyroxine, thyroid stimulating hormone (tsh), prolactin, insulin-like growth factor i (igf-i), dehydroepiandrosterone-sulfate (dhea-s), free and total testosterone (males only), and baseline growth hormone (gh). female patients also provide a menstrual history and undergo screening for hypogonadism. patients then undergo gh stimulation testing comprised of measurement of serum gh levels before and on 6 occasions during the 3 hours after receiving glucagon iv. after eating, patients undergo adrenocorticotropic hormone stimulation testing comprised of measurement of serum cortisol levels before and at 45 minutes after receiving corticotropin iv. phase ii: beginning at noon on a different day, patients with any abnormal endocrine tests during phase i undergo 24 hour inpatient dynamic testing of the neuroendocrine system. patients undergo gh stimulation testing comprised of measurement of serum gh levels before and on 4 occasions during the 2 hours after receiving levodopa. patients also undergo concurrent thyrotropin releasing hormone (trh) and gonadotropin releasing hormone (gnrh) stimulation testing comprised of measurement of serum tsh and luteinizing hormone (lh) levels before and at 15, 30, 60, and 90 minutes after receiving trh and gnrh iv. patients then undergo overnight metyrapone testing comprised of baseline measurement of serum 11-deoxycortisol and cortisol levels, followed by oral metyrapone with a snack, overnight fasting, and then remeasurement of serum 11-deoxycortisol and cortisol levels.

Eligibility criteria:
protocol entry criteria: --disease characteristics-- * closed head injury that occurred at least 3 months ago * must be admitted to the transitional learning community in galveston, texas, for rehabilitation --prior/concurrent therapy-- * no concurrent oral contraceptives or hormone replacement therapy --patient characteristics-- * mentally competent * no legal guardian * not pregnant or nursing

Keywords: brain injury neurologic and psychiatric disorders rare disease